She left the imaging centre on a Tuesday with a piece of paper that said “suspicion” and a question nobody answered: so who calls me now? She is not a real patient; she is the one any of us has seen in an October waiting room. What comes after that piece of paper, the stretch from suspicion to treatment, is the one the Chilean system decided to guarantee two decades ago. And it is also the stretch where it pays to look at what happens to the information that travels with her, or does not.

Chile’s Explicit Health Guarantees (GES), under the decree in force since January 2026, set maximum waiting times for breast cancer in people aged 15 and over: 45 days for diagnosis from suspicion, 45 days for staging from confirmation, 30 days to start treatment, 20 for adjuvant therapy and 90 for the first follow-up. Five separate, linked clocks, each starting at a defined clinical and administrative milestone, not at the mere act of writing something down. If her suspicion is not formalised under the criteria the rule requires, her first clock does not start; if the confirmation does not reach the breast unit, neither does the second. Two things should be kept apart: the legal deadline, which is her right, and the failure to notify or record, which is a management problem. The second does not erase the first.

I propose a hypothesis, plausible but not demonstrated for Chile by a local study: one possible source of delay is the discontinuity of information between points in the network. An illustrative, not universal, route crosses at least three doors, the primary care centre where her suspicion arose, the imaging centre that confirmed it and the oncology unit that will treat her, and at each door the system asks her again who she is, what she has and what was done to her. When the data do not travel with her, she repeats. Perhaps most revealing is that the guarantee measures the recorded stretches precisely and needs, to see the rest, a traceability audit comparing the date of the order with the date of notification.

For the organisation caring for her, this has concrete consequences. An aggregate compliance indicator hides where the delay occurs, because 45, 45, 30, 20 and 90 days do not fail in the same way. Traceability, that is, knowing exactly where on the route each woman is, is part of making the guarantee real and not a separate IT project. And the back-referral, the return to primary care with a summary that can actually be used, is what closes the loop so the next suspicion does not start from zero.

There is an economic context that is not a cause but is a frame. In Chile, households pay more than a third of health spending out of pocket, according to the OECD’s comparable estimate for 2023; how much of that comes from tests repeated for lack of information nobody has measured yet, and it is a question a network could answer with its own data. Waiting is free for no one, least of all for her.

The data did not travel with the patient. That is the hypothesis, and also the audit worth doing.

Sources: Decree 29 of 2025, Ministry of Health, approving the Explicit Health Guarantees (published 16-01-2026). LeyChile · Superintendency of Health. Health guidance: breast cancer (health problem no. 8). · OECD. Health at a Glance 2025, “Health expenditure by financing scheme” (comparable estimate 2023).